Deaths linked to heparin-containing devices
This article was originally published in The Gray Sheet
Executive Summary
FDA received reports of 11 deaths and 86 non-fatal adverse events associated with heparin-containing devices between Jan. 1 and May 14, 2008, according to a June 3 notice. The agency, which did not release the brands of the devices involved in the reports, says it has not determined conclusively that contaminated heparin caused the events. Most of the reports (82%) were associated with heparin lock flush solutions, such as the type Baxter recalled in January (Hep-Lock) due to heparin contamination. Other implicated devices include heparin-coated oxygenators and circuits used during bypass procedures and heparin-coated vascular grafts. Medtronic recalled heparin-coated cardiopulmonary bypass devices last month, but the firm had not received any adverse event reports for the products (1"The Gray Sheet" May 12, 2008, p. 3). The agency also notes that in vitro diagnostics tests that monitor heparin injected into patients or use tubes containing heparin to collect unclotted blood might also be impacted by the contamination, though no problems have been reported to date
You may also be interested in...
Heparin seizure
FDA seizes 11 lots of tainted heparin Nov. 6, including some of the type used in medical devices, from Cincinnati-based Celsus Laboratories. The over-sulfated chondroitin contaminant identified in the seized product has previously been fingered as the cause of deaths and adverse events in supplies of the blood-thinning agent imported from China (1"The Gray Sheet" June 9, 2008, In Brief). Six of the seized lots were heparin lithium, used in vacutainer blood collection tubes, some in vitro diagnostics and as a coating for capillary tubes. The other five were pharmaceutical grade
Medtronic Recalls Certain Disposables Made With Contaminated Heparin
Safety concerns surrounding tainted lots of the anticoagulant drug heparin have moved more squarely into the device space with the "precautionary" recall of selected Medtronic products coated with the Carmeda BioActive surface
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.